Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ACADEMIA
ACADEMIA
- Japan’s Antimicrobial Use in 2022 Levels Off YOY, Down 31.5% from 2013
March 10, 2023
- Probe Panel Recognizes Professor’s COI over Glactiv Scandal, but Doubts Whether It Constitutes Bribery
February 24, 2023
- Investigators Doubt Mitsubishi’s Trial Data on Muse Cell Therapy; Program Aborted without Notice
February 17, 2023
- 80% of Medical Institutions Say Reimbursement Fees “Essential” to Introduce Formularies: Study
February 8, 2023
- Lewy Body Dementia Specialist Sees Aricept Approval Modification as Positive Move
December 6, 2022
- Building Delivery Scheme for Disease-Modifying Drugs for Alzheimer’s Is Critical: Academic Societies
November 30, 2022
- Obesity Society to Highlight Proper Use of Semaglutide If Label Expanded
November 29, 2022
- Japan Infectious Diseases Association Updates Guidelines after Xocova Approval
November 25, 2022
- Academic Societies Warn against Hoarding Meropenem as Supply Crunch Intensifies
November 21, 2022
- Researchers Launch Scientific Society for Oncolytic Virus Therapies
October 31, 2022
- Less than Half of Japan Prefectures Offer SMA Test under Newborn Screening Program: Survey
October 28, 2022
- Japan Expert Sees Lecanemab Initially Treating Only a Few Tens of Thousands of Patients with Immature Care Setup
October 12, 2022
- 3rd COVID-19 Shot for Kids Aged 5-11 Effective as Booster: Infectious Diseases Association
October 5, 2022
- Antimicrobial Use in 2021 Down 31.5% from 2013: Expert
October 5, 2022
- Ivermectin Fails in Investigator-Led COVID Trial Too
October 3, 2022
- Emergency Approval Push for Shionogi’s COVID Pill Not Profit-Driven: Academic Societies
September 9, 2022
- University of Tokyo to Open Pathogen Research Facility to Drug Makers, CROs to Accelerate Vaccine Development
September 8, 2022
- Academic Societies Urge Japan Govt to Approve Shionogi’s COVID-19 Pill
September 5, 2022
- Japanese Society of Formulary to Support Regional Initiatives: President
August 18, 2022
- High Hopes for Sanofi’s Enjaymo as Japan’s First CAD Therapy: Osaka University Professor
August 5, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…